Gilead Sciences (GILD) - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US3755581036

Gilead Sciences, Inc. is a biopharmaceutical company that focuses on discovering, developing, and commercializing medicines to address unmet medical needs globally. Operating in the United States, Europe, and other international markets, Gilead offers a diverse range of innovative products.

Specializing in infectious diseases such as HIV/AIDS and viral hepatitis, Gilead provides medications like Biktarvy, Veklury, and Epclusa. In the field of oncology, the company offers cutting-edge treatments like Yescarta and Trodelvy. Moreover, Gilead has developed products for pulmonary arterial hypertension and serious invasive fungal infections.

Established in 1987 and headquartered in Foster City, California, Gilead Sciences, Inc. has formed strategic collaborations with various leading biopharmaceutical companies to further advance its research and development efforts. The company's commitment to developing next-generation therapeutics for viral diseases underscores its dedication to improving global healthcare.

For more information about Gilead Sciences, Inc. and its wide array of pharmaceutical products and research initiatives, visit their official website at

AI improved, may contain errors or wrong assumptions

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Gilead Sciences (GILD) - Stock Price & Dividends

GILD Stock Overview

Market Cap in USD 89,192m
Sector Healthcare
Industry Drug Manufacturers - General
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 1992-01-22

GILD Stock Ratings

Fundamental 6.14
Dividend 7.15
Growth 5y 3.30
Rel. Performance vs Sector -2.58
Analysts 3.77
Fair Price Total Ret. 69.37
Fair Price DCF 167.94

GILD Dividends

Yield 12m 4.11%
Yield on Cost 5y 5.56%
Dividends CAGR 5y 3.55%
Payout Consistency 100.0%

GILD Growth Ratios

Growth 12m -5.82%
Growth Correlation 12m -6%
Growth Correlation 3m -21%
CAGR 5y 6.23%
CAGR / Mean Drawdown 0.53
Sharpe Ratio 12m -0.50
Alpha vs SP500 12m -20.82
Beta vs SP500 5y weekly 0.40
CAPM 6.31%
Average Daily Range 2m 1.76%
Regime Oscillator 22.71
Volatility GJR Garch 1y 20.84%
Price / SMA 50 -7.71%
Price / SMA 200 -4.91%
Current Volume 6056.8k
Average Volume 20d 7866.6k

External Links for GILD Stock

Wall Street JournalBenzingaYahoo Finance
X (Twitter)Stocktwits
Fund Manager Positions
What is the price of GILD stocks?
As of February 28, 2024, the stock is trading at USD 73.02 with a total of 6,056,844 shares traded.
Over the past week, the price has changed by +1.36%, over one month by -8.17%, over three months by -1.65% and over the past year by -6.24%.
Why is GILD stock down?
Check with which Index or Commodity GILD has the highest Correlation, do they have a common driver?
Review the Fundamentals to find weaknesses (Debt, low returns). Check the Performance of the Peer-Group to find out, if the entire sector is under pressure.
Period Return GILD Return S&P 500
1 Month -8.17% 4.00%
3 Months -1.65% 11.99%
12 Months -6.24% 29.39%
What is the forecast for GILD stock price target?
According to ValueRays Forecast Model, GILD Gilead Sciences will be worth about 75 in February 2025. The stock is currently trading at 73.02. This means that the stock has a potential upside of +2.75%.
Issuer Forecast Upside
Wallstreet Target Price 87 19.2%
Analysts Target Price 85.5 17.1%
ValueRay Target Price 75 2.8%

Gilead Sciences Inc: A Deep Dive into its History, Business, and Market Status

History of Gilead Sciences Inc

Founded in 1987, Gilead Sciences Inc has established itself as a leading biopharmaceutical company. With a focus on discovering, developing, and commercializing innovative therapeutics in areas of unmet medical need, the company has made significant strides in the medical field, especially in antiviral drugs to treat patients infected with HIV, hepatitis B, hepatitis C, and influenza.

Core Business and Side Ventures

The core business of Gilead Sciences revolves around its robust antiviral drug portfolio, which has been pivotal in treating and managing HIV/AIDS and viral hepatitis. This segment not only brought commercial success but also established Gilead as a leader in the antiviral domain.

Beyond its antiviral lineup, Gilead has diversified its portfolio to include oncology, inflammatory and respiratory diseases, and cardiovascular conditions. This diversification reflects the company's commitment to addressing more therapeutic areas. Additionally, Gilead has embraced partnerships and acquisitions as strategies to bolster its R&D capabilities and expand its product offerings.

Current Market Status

As of now, Gilead Sciences continues to be a significant player in the pharmaceutical industry, maintaining a strong market position. The demand for its antiviral products remains high, contributing substantially to its revenue. Moreover, Gilead's efforts in expanding into new therapeutic areas and strategic acquisitions have positioned it well for future growth amid a competitive landscape.

Despite facing challenges such as patent expirations and market competition, Gilead's innovative pipeline and proactive business strategies give it a promising outlook. The company's commitment to improving patient care globally keeps it at the forefront of the biopharmaceutical industry.